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Abstract 
Objective: To explore a novel natural polymer, pullulan for controlling the release of fenoverine from matrix tablets and to elucidate the release 
kinetics of fenoverine from pullulan and HPMC matrices.  
Methods: In this study we formulated monolithic matrix tablets containing of fenoverine as controlled-release tablets by direct compression using 
pullulan, HPMC (Hydroxypropyl methyl cellulose) K4M and HPMC K100M polymers and evaluated for hardness, thickness, friability, weight 
variation drug content, in vitro drug release characteristics and FTIR (Fourier transform infrared spectroscopy) and DSC (Differential scanning 
calorimetry) study. 
Results: All the formulations showed compliance with pharmacopoeial standards. FTIR and DSC study indicated the absence of interaction between 
fenoverine and excipients. The formulation was optimized on the basis of acceptable tablet properties and in vitro drug release. The results of 
dissolution studies indicated that the formulation F5 [drug to polymer 1: 0.35] exhibited highest % cumulative drug release of 96.82±0.75 % at the 
end of 12 h. Optimised batch F5 showed super case II transport mechanism and followed zero order release kinetics. Short-term stability studies of 
the optimized formulation indicated that there were no significant changes observed in hardness, drug content and in vitro dissolution studies at the 
end of three months period. Similarity factor f2 was found to be 89, which indicated similar dissolution profiles before and after stability study. 
Conclusion: Based on above results we conclude that pullulan can be used as a polymer for retarding the release of drug from matrix formulations. 
Keywords: Pullulan, Fenoverine, Hydroxypropyl methyl cellulose, Controlled release, In vitro 




Controlled release systems include any drug delivery system that 
achieves slow release of drug over an extended period of time. 
Possible benefits of a properly designed controlled release dosage 
form include low cost, simple processing, improved efficacy, reduced 
adverse events, flexibility in terms of the range of release profile 
attainable, increased convenience and patient compliance [1, 2]. In 
recent years oral, controlled drug delivery systems have gained 
increased importance and interest since it is necessary to improve 
the systemic absorption of the drugs and patient compliance. In 
addition, controlled drug delivery systems maintain uniform drug 
levels, reduce the dose, side effects, and increase the safety margin. 
There are several types of controlled release systems that are 
designed and categorized according to the mechanism they employ. 
These include diffusion controlled, dissolution controlled, erosion 
controlled, ion exchange controlled and transport controlled also 
known as osmotic pump system [3, 4, 30]. Matrix controlled release 
tablet formulations are the most fashionable and straightforward to 
formulate on a commercial scale. Matrix tablets serves as an 
important tool for oral controlled-release dosage forms. Hence, 
problems of conventional dosage forms, like patient non-
compliance, local side effects, frequent administration and 
fluctuations in blood concentration levels were solved. Oral 
controlled release drug delivery system becomes a very promising 
approach for those drugs that are given orally but having the shorter 
half-life and high dosing frequency [1]. Matrix tablets may be 
formulated by wet granulation or direct compression methods by 
dispersing solid particles within a porous matrix formed of 
hydrophilic and hydrophobic polymers [5]. The drug release in 
matrix drug delivery systems occur by both dissolution-controlled 
as well as diffusion controlled mechanisms [6-8]. The present work 
was intended to explore the natural polymer obtained from 
Aureobasidium Pullulan [9, 10, 26-29]. This natural polymer is 
extremely hydrophilic in nature. This polymer has been used for film 
forming ability by other researchers, novelty of study is its use as 
release retarding agent has not been explored. Fenoverine is 
chemically 10[4-piperonyl [1-piperazinyl] acetyl] phenothiazine 
with molecular formula C26H25N3O3S [11, 12]. Fenoverine is an 
antispasmodic drug. It is used to relieve muscle spasm, used for 
disorders of the colon [Irritable bowel syndrome], abdominal pain, 
etc. [13, 14]. Fenoverine acts by modulating the gradient of calcium 
ions through the cell membrane. Fenoverine due to its poor aqueous 
solubility and poor wettabilty, less protein binding and its short 
biological half-life [5 to7 h] and therapeutic use in chronic 
conditions necessitates its formulation into controlled release 
dosage form [15, 16]. The objective of this investigation was to 
explore pullulan for its drug release controlling characteristics from 
controlled release dosage form. 
MATERIALS AND METHODS  
Materials 
Fenoverine was a gift from Euro drug Laboratories, Hyderabad, 
India. HPMC K4M was procured from SD Laboratories, Mumbai, 
India, HPMC K100M from Research Lab., Fine Chemicals, Mumbai, 
India. Pullulan was procured from Gangaval chemicals, Mumbai, 
Spray dried lactose was obtained from Okasa Pharma, Satara, India. 
Talc and magnesium stearate were purchased from Loba Chemie 
Pvt. Ltd., Mumbai, India. All other ingredients used throughout the 
study were of analytical grade and were used as received. 
Methods 
FTIR spectrum of fenoverine 
The IR spectrum of fenoverine was recorded using Fourier transform 
infrared spectroscopy [ATR-FTIR] to check its purity. The spectrum 
was recorded over the wave number of 4000 to 400 cm-1[19, 20]. 
Differential scanning calorimetry [DSC] of Fenoverine 
DSC study was carried by using Mettler-Toledo DSC 821e instrument 
[Switzerland]. About 2 mg of the fenoverine was sealed in the 
aluminum pan and heated at the rate of 10 °C/min, covering a 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 9, Issue 2, 2017 
Kulkarni et al. 
Int J App Pharm, Vol 9, Issue 2, 2017, 1-9 
 
2 
temperature range of 30 °C to 200 °C under a nitrogen atmosphere, 
at flow rate of 40 ml/min [21]. 
Drug–polymer compatibility study 
FTIR study  
FTIR spectra of HPMC K4M, HPMC K100M, pullulan and physical 
mixtures of fenoverine with polymer were recorded to study the 
interaction between them. The spectra were recorded over the wave 
number of 4000 to 400 cm-1[19, 20].  
DSC study 
In order to assess the compatibility of fenoverine with a polymer, 
thermogram of pure fenoverine, HPMC K4M, HPMC K100M, pullulan 
polymers and formulations were recorded using Mettler-Toledo DSC 
821e instrument [Switzerland]. About 5 mg of the physical mixture 
was sealed in the aluminium pan and heated at the rate of 10 
°C/min, covering a temperature range of 30 °C to 200 °C under a 
nitrogen atmosphere, at a flow rate of 40 ml/min [21, 25]. 
Formulation of controlled release tablets 
Controlled release matrix tablets of fenoverine were prepared by using 
different concentrations of pullulan, HPMC K4M and HPMC K100M table 
1. The entire excipients without talc were blended uniformly. After 
sufficient mixing of drug with other excipients, talc was added and 
further mixed for 5 min. The prepared powder mass was compressed 
with 11 mm punch on multi tooling compression machine [Rimek II 
Karnavati Eng. Ltd. Ahmedabad] to give a tablet of 500 mg weight. 
 
Table 1: Formula for controlled release tablets 
Ingredients F1 F2 F3 F4 F5 F6 F7 
Fenoveine 300 300 300 300 300 300 300 
HPMC K4M 120 150 - - - - - 
HPMC K100M - - 120 150 - - - 
Pullulan - - - - 120 150 180 
Spray dried lactose 60 30 60 30 60 30 - 
Talc 10 10 10 10 10 10 10 
Magnesium stearate 10 10 10 10 10 10 10 
Total 500 500 500 500 500 500 500 
Note: All quantities are given in mg 
 
Evaluation of tablets 
Hardness and thickness 
The hardness [kg/cm2] of the prepared formulations was 
determined by using a Monsanto hardness tester and thickness was 
measured by micrometre screw gauge [mm] [n = 3] [22]. 
Friability 
Friability of the prepared formulations was determined by using 
Roche friabilator [Campbell Electronics, Mumbai, India] [n = 20]. The 
tablet samples corresponding to 6.5 g were weighed accurately, 
placed in the drum. Drum was rotated 100 times, and then tablets 
were removed. Any loose dust from the tablets was removed, and 
accurate weight was taken, and the % friability was calculated from 
the weight of tablets before and after test [22]. 
Weight variation test 
The weight of the tablet is measured to ensure that a tablet contains 
the specific and accurate amount of drug and excipients. Twenty 
tablets were selected randomly and weighed. The average weight of 
the tablet was determined. Not more than the two of the individual 
weights deviate from the average weight by more than 5 % and none 
deviates by more than 10% [n = 20] [22].  
Drug content uniformity 
Ten tablets were weighed and finely powdered, and powder 
equivalent to 300 mg of drug was accurately weighed and dissolved 
in 0.1 N HCl [pH 1.2 buffer]. The resulting solution was suitably 
diluted with 0.1N HCl [pH 1.2 buffer] and analyzed by Shimadzu UV 
spectrophotometer at 230 nm [13, 22, 31 ]. 
In vitro drug release study 
The USP type II rotating paddle method was used to study the drug 
release from the controlled release tablet. The dissolution medium 
used was 900 ml 0.1 N HCl [buffer pH 1.2]. The release study was 
performed at 37±0.5 °C, with a rotation speed at 100 rpm. Sample 
volumes of 0.5 ml were withdrawn at predetermined time intervals 
and filtered through 0.2 µm Whatman filter paper and analyzed after 
appropriate dilution by Double beam UV spectrophotometer at 230 
nm. Sink conditions were maintained throughout the study. The 
study was carried out in triplicate [13]. 
Kinetics of in vitro drug release 
To study the release kinetics of in vitro drug release, data was 
treated with different kinetic equations such as Zero order (equation 
1), First order (equation 2), Hixon-Crowel (equation 3), Higuchi 
(equation 4) and Korsmeyer-Peppas (equation 5). 
Zero order kinetics  
W = k1t ………………. (1) 
First order Kinetics  
In100 − W = In100 − kt ……………. (2) 
Hixon-Crowell's Cube-Root Equation [Erosion Model]  
10 ° − W1/3=1001/3-k₃t ……………………… (3) 
Higuchi’s Square Root of Time Equation [Diffusion Model] 
W = k₄t½……………………………………. (4) 
Korsmeyer peppers Equation [Diffusion/Relation Model]  
Mt/M = k₅tⁿ ……………………………. (5) 
Where, W is % drug release at time t and K1–K4 are release rate 
constants, depending on the kinetic model used. Mt/M is the fractional 
drug release into the dissolution medium and K5 is a constant 
incorporating the structural and geometric characteristics of the tablet. 
The term n is the diffusional constant that characterizes the drug release 
transport mechanism. When n = 0.5, then the drug release mechanism is 
Fickian diffusion. If n<0.5 the mechanism is quasi-Fickian diffusion, and 
0.5<n<1.0, then it is non-Fickian or anomalous diffusion and when n = 
1.0 mechanism is non Fickian case II diffusion or zero order release 
kinetics could be observed [23, 24]. 
Stability studies  
Optimised formulation was sealed in aluminium packaging 
coated internally with polyethene, and kept instability chamber 
maintained at a temperature of 45 °C±2 °C and relative humidity 
75%±5% for 3 mo. Samples were withdrawn at 0, 30, 60 and 90 
d and evaluated for the hardness, drug content and in vitro 
dissolution test [32].  
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RESULTS AND DISCUSSION 
FTIR study 
The IR spectrum of drug exhibited distinctive peaks at 1038.46 [cm-
1] due to C-N stretch [aliphatic amines] and peaks at 1234.24 [cm-1] 
due to C-N stretch [aromatic amines]. The peaks at 1670.07 [cm-1] 
due to C=O stretching, peak at 2808.73[cm-1] due to C-H stretching, 
at 2964.65[cm-1] due to C=C-H stretching and at 2931.26 [cm-1] due 
to C-C-H stretching fig. 1. 
DSC study 
The DSC thermogram of the drug depicted a peak at 141.29 °C 
corresponding to the melting transition temperature of fenoverine. 
This indicated that fenoverine drug was in pure state fig. 2. 
  
 
Fig. 1: FTIR spectrum of fenoverine 
Note-sample size 5 mg 
 
 
Fig. 2: DSC thermogram of fenoverine 
Note-Sample size 2 mg 
 
Drug–polymer compatibility study 
FTIR study 
The IR spectra of pure drug and formulations were found similar 
with each other. The main absorption bands of the drug appeared in 
the formulation spectra shown in table 2, fig. 3, 4, 5. It was proved 
that the peaks found in pure drug and formulations are similar. Thus 
incorporation of drug in polymer did not change the position of its 
functional groups. This indicated that there was no difference 
between the internal structures and conformation of these samples 
at the molecular level. Hence FTIR study ruled out any possible 
interaction between drug and polymer. 
DSC study 
DSC thermogram of formulations containing pullulan, HPMC 
K4M and HPMC K100M fig. 6, 7, 8 showed a peak at 137.52 °C, 
141.14 °C and 140.76 °C respectively. There was no any 
significant shifting in the peaks of the drug, so it indicated that 
there was no any interaction between drug and formulation 
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1 2810 2808.73 2807.20  2808.08  2810.96  C-H Stretch 
2 2973 2964.65 2968.26  2923.14  2967.26  C=C-H Stretch 
3 2930 2931.26 2920.84  2923.84 2927.31  C-C-H Stretch 
4 1672 1670.07 1668.06  1667.24  1668.50  -C=O Stretch 
5 1042 1038.46 1032.24  1035.72  1035.00  C-N Stretch 
[Aliphatic amines] 
6 1238 1234.24 1235.54  1234.08  1234.40  C-N Stretch 
[Aromatic amines] 
Note-cm-1-per centimeter, HPMC-hydroxy propyl methyl cellulose 
 
 
Fig. 3: FTIR spectra of A] Fenoverine B] Pullulan C] Formulation containing pullulan 
 
 
Fig. 4: FTIR spectra of A] Fenoverine B] HPMC K4M C] formulation containing HPMC K4M 
Kulkarni et al. 




Fig. 5: FTIR spectra of A] Fenoverine B] HPMC K 100M C] formulation containing HPMC K100M 
 
 
Fig. 6: DSC thermogram of A] Fenoverine B] Pullulan C] formulation containing pullulan 
 
 
Fig. 7: DSC thermogram of A] Fenoverine B] HPMC K4M C] formulation containing HPMC K4M 
Kulkarni et al. 




Fig. 8: DSC thermogram of A] Fenoverine B] HPMC K100M C] formulation containing HPMC K100M 
 
Evaluation of tablets 
Hardness and thickness 
Hardness of tablets from all batches was found to be in the range of 
4.5±0.003 kg/cm2to 4.9±0.006 kg/cm2. All tablets were found hard 
enough so that they could easily withstand the handling and storage 
conditions without getting broken. Thickness of tablets ranged from 
2.1447±0.02 to 2.2866±0.13 mm. This indicated [1] uniform die fill 
[2] uniform density [3] compression pressure applied was uniform 
and [4] drug particles have uniform size and shape. 
Friability 
All the tablets exhibited acceptable friability as none of the tested 
batches showed percentage friability that exceeded 1%. As per IP, % 
friability below 1% is an indication of good mechanical resistance of 
the tablets. % friability of all batches found in the range of 0.61%-
0.78 %. Thus, it was proved that tablets could withstand the 
pressure, mechanical shocks during handling, transportation, 
storage and manufacturing processes.  
Weight variation test 
Weight variation test showed that all tablets were found within the 
range of 494.7 mg–497.45 mg. None of the tablets deviated from the 
stated specification i.e.±5%. It is in the limits specified by IP [22]. This 
indicated uniform flow property, die fill and compression pressure. 
Drug content  
Drug content of all the formulation batches was found to be between 
95.7±0.002 to 99.69±0.004. Hence, it can be concluded that all the 
formulations are having accurate amount of drug distributed 
uniformly in powder mass and followed acceptable limits as per IP 
[22]. i.e. 85 to 115 % of average content table 3. 
 
Table 3: Evaluation parameters of tablets 
Batches Thickness* [mm] Hardness* [kg/cm2] Friability [%] Average Weight [mg] Drug content [%] 
F1 2.227±0.09 4.955±0.05 0.65 496.63 98.3±0.003 
F2 2.227±0.07 4.933±0.07 0.75 497.45 96.74±0.003 
F3 2.278±0.11 4.955±0.07 0.78 497.26 95.7±0.002 
F4 2.257±0.14 4.935±0.05 0.65 495.76 96.4±0.001 
F5 2.286±0.13 4.733±0.21 0.68 494.7 96.69±0.004 
F6 2.198±0.04 4.6±0.17 0.66 496.32 99.11±0.003 
F7 2.147±0.02 4.622±0.21 0.61 495.99 99.24±0.001 
* mean±SD [n = 3] 
 
In–vitro release study 
The results of in–vitro dissolution study given in table 4 and in fig. 9, it 
was observed that an increase in polymer concentration from 24 to 30% 
(F1-F2 and F3-F4) and from 24 to 36 % (F5 to F7) there is a decrease in 
release rate. The drug release from formulations containing HPMC 
K100M (F3-F4) was found to be less as compared to other formulations. 
This might be due to slow hydration of matrix and its property to form a 
thick gel layer, which retards the drug release from the tablet. Whereas 
formulations containing pullulan [F5-F7] gave higher drug release as 
compared to other formulations, which may be due to quick hydration 
and erosion of polymer matrix. As compared pullulan, HPMC polymers 
are less hydrophilic and require more time to get hydrated. In addition to 
the concentration of polymer matrix, the type and viscosity of polymer 
also influence on drug release.  
In–vitro dissolution study data shows cumulative drug release was 
in the order like F5>F1>F6>F2>F7>F3>F4. This might be due to the 
nature, viscosity and concentration of the various polymers used. 
Pullulan has powerful retardant property resulting in a matrix 
formation which is required for sustained release formulations. The 
data also indicated that because of quick hydration and erosion of 
pullulan polymer there was more drug release in 2 h, 4 h, 6 h etc. as 
compared to HPMC polymers. Formulation F5 was considered as 
optimized formulation as it showed highest cumulative % drug 
release i.e. 96.82±0.75 % at the end of 12 h. 
The tablets with pullulan polymer showed comparative dissolution 
profile with tablets with HPMC polymers and showed drug release 
rate retarding properties. 
Kinetics of in vitro drug release 
The in vitro release data obtained were fitted into various kinetic 
models Optimized batch F5 showed case II transport mechanism 
[n>1] i.e. drug transport mechanism associated with stresses and 
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state transition in hydrophilic glassy polymers which swell in water 
or biological fluids, also includes polymer disentanglement and 
erosion and followed zero order release pattern showed in table 5. 
So, predominant drug release mechanism is controlled release. 
 




F1 F2 F3 F4 F5 F6 F7 
0 0 0 0 0 0 0 0 
1 1.89±0.14 6.45±0.13 5.73±0.7 3.07±0.48 12.89±0.73 8.54±0.55 11.92±0.72 
2 7.29±0.46 10.14±0.42 12.26±0.25 11.64±0.91 19.74±0.64 13.21±0.3 14.88±1.25 
3 11.03±0.12 13.19±0.39 15.89±0.38 11.84±0.62 25.68±1.22 17.38±0.66 18.72±0.53 
4 13.73±0.59 16.33±0.64 20.61±0.58 16.42±0.91 33.07±0.6 19.89±0.74 21.63±0.92 
5 17.67±0.4 18.39±0.42 23.96±0.49 20.56±1.22 43.71±0.17 24.76±0.56 25.5±0.27 
6 21±0.19 22.77±0.48 31.44±0.33 30.75±0.74 54.04±0.5 29.21±1.13 39.16±0.23 
7 31.49±0.32 40.34±0.6 40.06±0.18 43.78±0.65 62.21±0.76 36.06±1.11 43.58±0.52 
8 49.13±0.26 54.38±0.59 52.82±1.06 53.5±0.55 69.42±0.41 48.41±0.38 49.94±0.98 
9 53.89±0.21 67.59±0.31 60.38±0.3 60.99±0.78 77.05±0.64 56.74±0.9 62.19±0.69 
10 61.52±0.23 72.62±0.47 67.51±0.48 67.47±0.98 83.09±0.16 66.48±0.79 66.51±1.18 
11 67.32±0.23 75.5±0.51 73.44±1.47 71.95±1.12 88.27±0.57 74.18±1.04 79.68±0.14 
12 88.62±0.16 85.34±0.92 80.12±0.8 78.12±0.99 96.82±0.75 85.96±0.69 83.77±0.42 
* mean±SD [n = 3] 
 
 
Fig. 9: In vitro drug release profile of formulations F1 to F7 
Note-error bars omitted 
 
Table 5: Study of various kinetic models 
Batch Zero order  First order  Higuchi  Hixson-Crowell Korsemeyer-peppas  Best fit model 
r2 r2 r2 r2 r2 n 
F1 0.946 0.696 0.869 0.939 0.973 1.889 K-peppas 
F2 0.942 0.957 0.872 0.968 0.985 1.700 K-peppas 
F3 0.983 0.902 0.933 0.969 0.992 1.636 K-peppas 
F4 0.973 0.782 0.928 0.928 0.928 1.736 K-peppas 
F5 0.994 0.920 0.976 0.960 0.983  1.594 Zero order 
F6 0.958 0.979 0.882 0.994 0.983 1.606 H. Crowell 
F7 0.955 0.982 0.880 0.992 0.979 1.601 H. Crowell 
 
Stability studies 
Short-term stability studies of the optimised formulation indicated that 
there were no significant changes in hardness, drug content and in vitro 
dissolution studies at the end of three months period table 6, 7, and fig. 
10, P ‹ 0.05. Similarity factor f2 of dissolution profiles of optimized 
formulation F5 before and after stability study was found to be 89, which 
indicated similar dissolution profiles before and after stability study. 
 
Table 6: Stability study data of formulation F5 
Parameters 0 Mo 1 Mo 2 Mo 3 Mo 
Hardness*[kg/cm2] 4.7±0.2 4.7±0.2 4.6±0.1 4.6±0.1 
Drug content* [%] 99.69±0.004 99.57±0.01 98.59±0.09 98.21±0.09 
 *mean±SD [n = 3] 
Kulkarni et al. 
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Table 7: In vitro dissolution study of formulation F5 before and after stability 
Time 
[H] 
Cumulative % drug release at 
0 Mo 1 Mo 2 Mo 3Month 
0 0 0 0 0 
1 12.89±0.73 12.80±0.01 12.44±0.31 12.10±0.11 
2 19.74±0.64 19.55±0.5 19.41±0.26 18.45±0.01 
3 25.68±1.22 25.39±0.37 25.23±0.01 24.50±0.33 
4 33.07±0.6 33.00±0.53 32.84±0.13 32.06±0.05 
5 43.71±0.17 43.56±0.45 43.25±0.17 42.30±26 
6 54.04±0.5 54.11±0.09 53.98±0.01 53.16±0.01 
7 62.21±0.76 62.1±0.11 61.94±0.06 61.06±0.07 
8 69.42±0.41 69.09±0.12 68.79±0.27 68.20±0.13 
9 77.05±0.64 76.86±0.15 76.35±0.13 75.24±0.07 
10 83.09±0.16 83.09±0.01 82.97±0.01 81.17±0.05 
11 88.27±0.57 88.11±0.01 87.77±0.27 86.13±0.01 
12 96.82±0.75 96.42±0.20 95.30±0.12 94.63±0.26 
 * mean±SD [n = 3] 
 
 
Fig. 10: Dissolution profile of formulation F5 before and after stability study 
Note-error bars omitted 
 
CONCLUSION 
Fenoverine controlled release matrix tablets were prepared by using 
different concentrations of pullulan, HPMC K4M and HPMC K100M by 
direct compression method and evaluated. FTIR and DSC studies 
indicated that there were no drug-excipients interactions. In vitro drug 
release study showed that, as the amount of polymer increases, the 
drug release decreases. Optimized batch F5 showed case II transport 
mechanism and followed zero order release kinetics. Short-term 
stability studies of the optimized formulation indicated that there was 
no significant change observed in hardness, drug content and in vitro 
dissolution studies. Similarity factor f2 was found to be 89, which 
indicated similar dissolution profiles before and after stability study. 
Pullulan a novel natural polymer showed drug release controlling 
characteristics. Hence it can be concluded that pullulan can be used as 
a polymer for retarding the release of drug from matrix formulations. 
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